The hypomethylating agents Azacitidine and Cytarabine, frequently used in AML, were also shown to enhance FLT3 and KIT inhibition in combination with both Midostaurin, Quizartinib [17,18]. This evidence concerns the gene KIT and acute myeloid leukemia.